Kevin Eisele, managing director on William Blair’s equity capital markets team, joined the Wall Street Journal’s Venture Capital Pro Newsletter team to discuss how venture capital fundraising growth for biotech companies has exceeded 2023’s first quarter.
While the fundraising numbers are pointing in the right direction, Eisele noted that there’s still “caution” in the market.